Plancorp LLC Raises Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Plancorp LLC raised its position in shares of Eli Lilly and Company (NYSE:LLY) by 0.7% in the 2nd quarter, HoldingsChannel reports. The institutional investor owned 12,436 shares of the company’s stock after purchasing an additional 83 shares during the quarter. Eli Lilly and Company accounts for about 0.5% of Plancorp LLC’s holdings, making the stock its 26th biggest holding. Plancorp LLC’s holdings in Eli Lilly and Company were worth $11,259,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in the company. Sargent Investment Group LLC raised its position in Eli Lilly and Company by 11.5% during the 2nd quarter. Sargent Investment Group LLC now owns 2,563 shares of the company’s stock valued at $2,320,000 after purchasing an additional 264 shares during the last quarter. DHK Financial Advisors Inc. purchased a new position in Eli Lilly and Company during the second quarter valued at $209,000. Edgestream Partners L.P. boosted its holdings in shares of Eli Lilly and Company by 150.3% during the 2nd quarter. Edgestream Partners L.P. now owns 13,387 shares of the company’s stock valued at $12,120,000 after buying an additional 8,039 shares in the last quarter. GDS Wealth Management purchased a new stake in shares of Eli Lilly and Company in the 2nd quarter worth about $240,000. Finally, Pekin Hardy Strauss Inc. increased its stake in shares of Eli Lilly and Company by 10.6% in the 2nd quarter. Pekin Hardy Strauss Inc. now owns 1,356 shares of the company’s stock worth $1,228,000 after acquiring an additional 130 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Insiders Place Their Bets

In other news, major shareholder Lilly Endowment Inc sold 210,000 shares of the business’s stock in a transaction on Wednesday, July 10th. The shares were sold at an average price of $939.82, for a total transaction of $197,362,200.00. Following the completion of the sale, the insider now owns 96,943,810 shares of the company’s stock, valued at approximately $91,109,731,514.20. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Over the last ninety days, insiders have sold 451,900 shares of company stock worth $418,732,178. Company insiders own 0.13% of the company’s stock.

Eli Lilly and Company Stock Performance

LLY stock opened at $924.05 on Tuesday. The company has a debt-to-equity ratio of 1.74, a current ratio of 1.11 and a quick ratio of 0.87. Eli Lilly and Company has a 1 year low of $516.57 and a 1 year high of $972.53. The company has a market cap of $878.22 billion, a P/E ratio of 136.09, a price-to-earnings-growth ratio of 2.79 and a beta of 0.42. The stock’s fifty day moving average price is $897.24 and its 200-day moving average price is $835.09.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, August 8th. The company reported $3.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.64 by $1.28. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. The business had revenue of $11.30 billion for the quarter, compared to analysts’ expectations of $9.83 billion. On average, equities analysts forecast that Eli Lilly and Company will post 16.49 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 10th. Shareholders of record on Thursday, August 15th were issued a dividend of $1.30 per share. The ex-dividend date of this dividend was Thursday, August 15th. This represents a $5.20 dividend on an annualized basis and a yield of 0.56%. Eli Lilly and Company’s dividend payout ratio is currently 76.58%.

Analyst Upgrades and Downgrades

LLY has been the subject of a number of analyst reports. Wells Fargo & Company raised their target price on shares of Eli Lilly and Company from $875.00 to $1,000.00 and gave the company an “overweight” rating in a research note on Friday, August 9th. Barclays raised their price objective on Eli Lilly and Company from $913.00 to $1,025.00 and gave the company an “overweight” rating in a research report on Wednesday, July 10th. BMO Capital Markets increased their target price on Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the stock an “outperform” rating in a research note on Friday, August 9th. Truist Financial reaffirmed a “buy” rating and issued a $1,000.00 price target (up previously from $892.00) on shares of Eli Lilly and Company in a research report on Tuesday, June 25th. Finally, Citigroup started coverage on shares of Eli Lilly and Company in a research report on Friday. They set a “buy” rating and a $1,060.00 price objective on the stock. Three equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $977.35.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.